BR0313724A - Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz - Google Patents

Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz

Info

Publication number
BR0313724A
BR0313724A BR0313724-4A BR0313724A BR0313724A BR 0313724 A BR0313724 A BR 0313724A BR 0313724 A BR0313724 A BR 0313724A BR 0313724 A BR0313724 A BR 0313724A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
relates
compound
Prior art date
Application number
BR0313724-4A
Other languages
English (en)
Inventor
Amy Mae Bunker
Joseph Armand Picard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0313724A publication Critical patent/BR0313724A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE AZAISOQUINOLINA COMO INIBIDORES DE METALOPROTEINASE DE MATRIZ". A presente invenção refere-se a compostos definidos pela Fórmula I ou um seu sal farmaceuticamente aceitável, em que R^ 1^ , Q, Y, R^ 2^, R^ 3^, R^ 4^, R^ 5^ e n são como definido no relatório descritivo. A invenção também refere-se a composições farmacêuticas compreendendo um composto de Fórmula I, ou um seu sal farmaceuticamente aceitável, como definido no relatório descritivo, juntamente com um veículo, diluente ou excipiente farmaceuticamente aceitável. A invenção também refere-se a métodos de inibição de uma enzima MMP-13 em um animal, compreendendo a administração ao animal de um composto de Fórmula I, ou de um seu sal farmaceuticamente aceitável. A invenção também refere-se a métodos de tratamento de uma doença mediada por uma enzima MMP-13 em um animal, compreendendo a administração ao animal de um composto de Fórmula I, ou de um seu sal farmaceuticamente aceitável, quer sozinho ou em uma composição farmacêutica. A invenção também refere-se a métodos de tratamento de doenças tais como doença cardíaca, esclerose múltipla, osteoartrite e artrite reumatóide, outras artrites para além de osteoartrite ou artrite reumatóide, insuficiência cardíaca, doença inflamatória do intestino, insuficiência cardíaca, degeneração macular relacionada com a idade, doença pulmonar obstrutiva crónica, asma, doenças periodontais, psoríase, aterosclerose e osteoporose em um paciente, compreendendo a administração ao paciente de um composto de Fórmula I, ou de um seu sal farmaceuticamente aceitável, quer sozinho ou em uma composição farmacêutica. A invenção também refere-se a combinações, compreendendo um composto de Fórmula I, ou um seu sal farmaceuticamente aceitável, juntamente com ou componente ativo farmaceuticamente como descrito no relatório descritivo. Novo quadro reivindicatório (total de 8 reivindicações), incorporando as emendas às reivindicações, conforme relatório de exame preliminar.
BR0313724-4A 2002-08-13 2003-08-04 Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz BR0313724A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40321902P 2002-08-13 2002-08-13
PCT/IB2003/003485 WO2004014866A1 (en) 2002-08-13 2003-08-04 Azaisoquinoline derivatives as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR0313724A true BR0313724A (pt) 2005-06-28

Family

ID=31715962

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313724-4A BR0313724A (pt) 2002-08-13 2003-08-04 Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz

Country Status (8)

Country Link
US (1) US6977261B2 (pt)
EP (1) EP1539709A1 (pt)
JP (1) JP2006504665A (pt)
AU (1) AU2003249531A1 (pt)
BR (1) BR0313724A (pt)
CA (1) CA2495293A1 (pt)
MX (1) MXPA05001786A (pt)
WO (1) WO2004014866A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
WO2005087768A1 (en) * 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
CN101595109B (zh) * 2006-11-20 2012-09-05 百时美施贵宝公司 作为二肽基肽酶ⅳ抑制剂的7，8-二氢-1，6-二氮杂萘-5（6h）-酮和相关二环化合物及方法
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
TWI405565B (zh) * 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗－骨質流失及抗－牙周附連喪失之功效
ES2662072T3 (es) * 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
ES2446971T3 (es) * 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
ES2528404T3 (es) * 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
NZ617987A (en) 2011-05-10 2016-02-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (pt) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
CA3188639A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664912B2 (en) * 1992-09-02 1995-12-07 Dainippon Pharmaceutical Co. Ltd. Novel 3-oxadiazolyl-1,6-naphthyridine derivatives
ES2224130T3 (es) * 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
GB9711257D0 (en) * 1997-05-30 1997-07-30 Smithkline Beecham Plc Novel compounds
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2001096607A2 (en) * 2000-06-13 2001-12-20 The Trustees Of Boston University Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
MXPA03003734A (es) 2000-10-26 2003-07-28 Pfizer Prod Inc Inhibifores de metaloproteinasa del tipo pirimidin-2, 4, 6-triona.
EE200300196A (et) 2000-10-26 2003-10-15 Pfizer Products Inc. Spiropürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
US7374882B2 (en) * 2000-11-28 2008-05-20 Riken Method for base sequencing and biologically active nucleic acids
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000328A (es) * 2001-02-14 2003-08-30 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz
CA2433778A1 (en) * 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
ATE280164T1 (de) * 2001-02-14 2004-11-15 Warner Lambert Co Benzothiadiazine als matrix metallproteinase inhibitoren
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
PA8556301A1 (es) 2001-10-12 2003-09-05 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
EP1434585A1 (en) * 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
AU2002249275A1 (en) 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2002333256A1 (en) 2002-06-25 2004-01-06 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Also Published As

Publication number Publication date
JP2006504665A (ja) 2006-02-09
WO2004014866A1 (en) 2004-02-19
AU2003249531A1 (en) 2004-02-25
EP1539709A1 (en) 2005-06-15
US6977261B2 (en) 2005-12-20
MXPA05001786A (es) 2005-04-25
CA2495293A1 (en) 2004-02-19
US20040038961A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
BR0313724A (pt) Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
BR0313460A (pt) Derivados de naftaleno como inibidores de metaloproteinase da matriz
BR0313464A (pt) Derivados heterobiarilo como inibidores da metaloproteinase de matriz
DE60222264T2 (de) Phenylpyrazolderivate als seh-inhibitoren
BR0313384A (pt) Derivados de cromona como inibidores de metaloproteinases de matriz
DE60001745T2 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
AT392081B (de) Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen
EP1218341B1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0313459A (pt) Derivados monocìclicos como inibidores de metaloproteinases de matriz
BR0207910A (pt) HidantÈnios e sua utilização no tratamento do diabetes
DE102006026464A1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
EP1264828B1 (de) Urokinase-Inhibitoren
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
BR9808030A (pt) Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos
WO2008014685A1 (fr) Formulation contenant du tréhalose à des fins d'injection intraarticulaire
JP2008526953A (ja) 炎症性疾患のプラジカンテルでの治療
CN1997641A (zh) 用作钙通道阻断剂的二芳基胺衍生物
DE10041402A1 (de) Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
DE69727240T2 (de) Kombinationen, enthaltend VX478, Zidovudin und 3TC zur Behandlung von HIV
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
WO2013116713A9 (en) Treating neuropathic pain with seh inhibitors
US20180369210A1 (en) Methods and compositions for treating lysosomal storage disorders

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired